Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 06 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 8 pages · English

Summary by 6ix AI

The approval is based on extensive research and development efforts by Zydus and ensures compliance with USFDA standards regarding quality testing. This new drug combines sitagliptin and metformin hydrochloride to improve glycemic control in adults. The approval aims to enhance accessibility and affordability of diabetes treatment options in healthcare systems.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2023, titled "Zydus receives USFDA approval for ZITUVIMETTM to treat adult patients with type 2 diabetes mellitus".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases